Smart for Life (SMFL) Featured by New to the Street
Interviews to Air on National Television Including Bloomberg and Fox Business
MIAMI, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Smart...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Smart For Life (SMFL) $0.37 Announces Initiation of Equity Analyst Coverage by Dawson James...
Initiates with “Buy” recommendation and $8 price target.
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Smart for Life,...
Mpox Vaccines and ‘Emergency Use’ Authorization Explained.
mpox Vaccine EUAs
On November 28, 2022, the World Health Organization announced, and the U.S. government supported, renaming monkeypox disease...
Smart for Life (SMFL) Announces Letter of Intent to Acquire Largest Acquisition to Date.
6th Acquisition to Date is Expected to Add over $15 million of Revenue and to be Accretive to Earnings.
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that...
Revive Therapeutics (RVVTF) Annual Shareholder Meeting.
ANNUAL SHAREHOLDER MEETING
https://vimeo.com/752050831
13 Keys to a Successful FDA Advisory Committee Meeting (Regulatory Focus)
RAPS' Latest | 01 August 2019 | By Zachary Brousseau
When the US Food and Drug Administration (FDA) has significant...
Adding Progressive Care (RXMD) $0.04 to Watch List.
Adding to Biotech Stock Review 2022 Watch List.
Speculative, Yes. But Pay Down of $2 Million Toxic Note and...
CB Scientific, Inc. (CBSC) Announces FDA 510(k) Submission.
CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event Monitor
Updated product to include significant...
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
